Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.30 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20329382 | 0.83 | — | — | |
| SCHEMBL23916415 | 0.83 | PIK3CD (0.41) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL20329237 | 0.83 | MAPT (0.44) | — | |
| SCHEMBL6960829 | 0.83 | BRD4 (0.39) | AGTR1AGTR2 | |
| SCHEMBL21136103 | 0.82 | GAA (0.39) | CHEK1CYP11B1CYP11B2 | |
| SCHEMBL14281809 | 0.79 | CHEK1 (0.35) | CHEK1CYP11B1CYP11B2 | |
| SCHEMBL18334896 | 0.79 | CYP19A1 (0.39) | CHEK1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL20329401 | 0.79 | KDM4E (0.49) | CHEK1 | |
| SCHEMBL14217428 | 0.78 | ALDH1A1 (0.34) | — | |
| SCHEMBL20329240 | 0.77 | KDM4E (0.39) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317092-A1 | TETRAZOLE CONTAINING COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-10-14 | — | — | US | disclosed |
| US-20190194148-A1 | TETRAZOLE-CONTAINING 1,2-CYCLOPROPANE-CARBOXAMIDES | Bayer Pharma AG (DE) | 2019-06-27 | — | — | US | disclosed |
| US-20190194148-A1 | TETRAZOLE-CONTAINING 1,2-CYCLOPROPANE-CARBOXAMIDES | Bayer Pharma AG (DE) | 2019-06-27 | — | — | US | disclosed |
| WO-2018114783-A1 | TETRAZOLE CONTAINING COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317092-A1 | TETRAZOLE CONTAINING COMPOUNDS | TSLP, IL5, TRPA1 | CHEK1 4805/4885AGTR1 1707/4885AGTR2 1483/4885 |
| US-20190194148-A1 | TETRAZOLE-CONTAINING 1,2-CYCLOPROPANE-CARBOXAMIDES | HNMT, AANAT, CHRNA5 | CHEK1 4719/4885AGTR1 1515/4885AGTR2 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.